The Study Of Correlation Between Drug Treatment And The Changes Of Serum SICAM-1and IL-6Levels In Type2Diabetes With Cerebral Infarction

Objective: Chronic complications of type2diabetes not only seriouslyaffect the life quality of patients, but also bring the heavy economic burden tofamilies and society. The mainly chronic complication of diabetes is vascularcomplication throughout the body. Cerebral vascular disease is one of themacrovascular complications of diabetes, which is mainly characterized byischemic cerebrovascular disease, and that increases with age. In China, agingpopulation gradually increased and the danger of acute cerebral infarctionbecome more prominent. Currently, many studies have shown that somecytokines such as sICAM-1, IL-6are closely related with the occurrence anddevelopment of type2diabetes and its chronic complications. In this study,through examining the changes of serum sICAM-1and IL-6levels in type2diabetes and type2diabetes combined with cerebral infarction patients and theeffect of the drug on serum sICAM-1and IL-6levels, which is aimed atproviding clinical evidence for the treatment of type2diabetes and type2diabetes combined with cerebral infarction patients.Methods:60cases of hospitalized type2diabetic patients (group A) and60cases of hospitalized type2diabetes with cerebral infarction patients(group B) between September2010to September2011were selected fromEndocrinology of First Hospital of Hebei Medical University,30healthypersons as group C. Randomly divided group A into group A1and A2,Randomly divided group B into group B1and B2.All subjects were givenroutine treatment, group A1was treated with xueshuantong injection, groupA2was treated with ozagrel sodium injection on the basis of group A1.Group B1was treated with xueshuantong and ozagrel sodium injection,group B2was treated with edaravone injection on the basis of group B1. ELISA was used to determine the changes of serum sICAM-1and IL-6levelsbefore and after treatment in each group.Result:1The comparation of serum sICAM-1and IL-6levels in three groups (A, B,C), serum levels of sICAM-1(332.23±29.08) ng/mL and IL-6(15.12±1.72)ng/L of group B was significantly higher than sICAM-1(269.89±8.62)ng/mland IL-6(9.23±1.59) ng/L of group A, P<0.05. Serum levels of sICAM-1andIL-6of group A was significantly higher than sICAM-1(194.07±23.96) ng/mLand IL-6(6.19±1.32) ng/L of group C, P<0.05.2The comparation of serum sICAM-1and IL-6levels of group A1and A2before and after treatment, the results reflected serum levels of sICAM-1(256.37±9.97) ng/mL and IL-6(7.47±1.35) ng/L after treatment of group A1was significantly lower than sICAM-1(270.76±9.10) ng/mL and IL-6(9.03±1.52) ng/L before treatment, P<0.05. Serum levels of sICAM-1(245.88±10.7) ng/mL and IL-6(6.82±0.83) ng/L after treatment of group A2was significantly lower than sICAM-1(269.01±8.17) ng/mL and IL-6(9.01±1.13) ng/L before treatment, P<0.05. Group A2was decreased moresignificantly than in group A1.3The comparation of serum sICAM-1and IL-6levels of group B1and B2before and after treatment, Serum levels of sICAM-1(308.52±31.56) ng/mLand IL-6(12.77±1.84) ng/L after treatment of group B1was significantlylower than sICAM-1(333.63±31.40) ng/mL and IL-6(15.21±1.83) ng/Lbefore treatment, P<0.05. Serum levels of sICAM-1(299.84±27.74) ng/mLand IL-6(11.83±1.533) ng/L after treatment of group B2was significantlylower than sICAM-1(330.82±27.03) ng/mL and IL-6(15.03±1.64) ng/Lbefore treatment, P<0.05. Group B2was decreased more significantly than ingroup B1.Conclusion:1Serum sICAM-1, IL-6levels in type2diabetes combined with cerebralinfarction patients is higher than that in type2diabetic patients, SerumsICAM-1, IL-6levels in type2diabetic patients is higher than that in normal human.2Xueshuantong injection and ozagrel sodium injection can reduce serumsICAM-1, IL-6levels of type2diabetic patients, the effect of combination ofabove two is more significant than single injection of xueshuantong, andwhich could provide theory basis for clinical treatment.3After the patients of type2diabetes combined with cerebral infarction weretreated with edaravone injection, the life quality of the patients was improvedremarkably.